OncologyMerck
Merck Reports Phase 3 KEYNOTE-826 Results for Keytruda in Cervical Cancer
BMI
Biotechnology Media Insights
Editorial Team · November 12, 2023
Merck announces Phase 3 KEYNOTE-826 trial results showing Keytruda plus chemotherapy significantly improves overall survival in cervical cancer.
Merck today announced results from the Phase 3 KEYNOTE-826 trial evaluating Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. The trial met its primary endpoints, demonstrating significant improvements in overall survival and progression-free survival with Keytruda.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.